{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:13:04Z","timestamp":1784077984585,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI063517"],"award-info":[{"award-number":["R01AI063517"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI072219"],"award-info":[{"award-number":["R01AI072219"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI100560"],"award-info":[{"award-number":["R01AI100560"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jgar.2018.01.001","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T19:21:18Z","timestamp":1515698478000},"page":"146-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["DISC: Describing Infections of the Spine treated with Ceftaroline"],"prefix":"10.1016","volume":"13","author":[{"given":"Richard R.","family":"Watkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-1812","authenticated-orcid":false,"given":"George","family":"Yendewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Burdette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Horattas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nairmeen Awad","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Mangira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Salata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2018.01.001_bib0005","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.01.001_bib0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/infdis\/jit127","article-title":"Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus","volume":"208","author":"Vidaillac","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2018.01.001_bib0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jac\/dkv311","article-title":"In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme","volume":"71","author":"Karlowsky","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.01.001_bib0020","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2013.07.005","article-title":"Ceftaroline for methicillin-resistant Staphylococcus aureus bacteremia: case series and review of the literature","volume":"42","author":"Polenakovik","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.01.001_bib0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1179\/1973947813Y.0000000144","article-title":"Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience","volume":"25","author":"Santos","year":"2013","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2018.01.001_bib0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1179\/1973947814Y.0000000184","article-title":"Contemporary use of ceftaroline fosamil for the treatment of community-acquired pneumonia: CAPTURE study experience","volume":"26","author":"Ramani","year":"2014","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2018.01.001_bib0035","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/jac\/dkw001","article-title":"In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis","volume":"71","author":"Sanchez","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.01.001_bib0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/IPC.0b013e31825b2110","article-title":"Successful treatment of osteomyelitis from methicillin-resistant Staphylococcus aureus with ceftaroline","volume":"21","author":"Watkins","year":"2013","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.jgar.2018.01.001_bib0045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/1120009X.2017.1351729","article-title":"Ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case series","volume":"30","author":"Lalikian","year":"2018","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2018.01.001_bib0050","doi-asserted-by":"crossref","first-page":"496","DOI":"10.4103\/0377-4929.191798","article-title":"In vitro activity of ceftaroline: a novel antibiotic against methicillin-resistant Staphylococcus aureus","volume":"59","author":"Gaikwad","year":"2016","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.jgar.2018.01.001_bib0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.semarthrit.2008.03.002","article-title":"Pyogenic vertebral osteomyelitis: a systematic review of clinical characteristics","volume":"39","author":"Mylona","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jgar.2018.01.001_bib0060","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00296-016-3532-1","article-title":"Clinical features of septic discitis in the UK: a retrospective case ascertainment study and review of management recommendations","volume":"36","author":"Hopkinson","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jgar.2018.01.001_bib0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.55095\/achot2017\/006","article-title":"Pyogenic spinal infections in adults: a 5-year experience from a tertiary care centre","volume":"84","author":"D\u017eupov\u00e1","year":"2017","journal-title":"Acta Chir Orthop Traumatol Cech"},{"key":"10.1016\/j.jgar.2018.01.001_bib0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jinf.2013.11.011","article-title":"Increasing incidence of pyogenic spondylodiscitis: a 14-year population-based study","volume":"68","author":"Kehrer","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2018.01.001_bib0075","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1mg\/L: a matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.01.001_bib0080","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/cid\/cir932","article-title":"Methicillin-resistant Staphylococcus aureus and vancomycin: minimum inhibitory concentration matters","volume":"54","author":"Deresinski","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.01.001_bib0085","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.01.001_bib0090","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/cir147","article-title":"Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"52","author":"Saravolatz","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.01.001_bib0095","doi-asserted-by":"crossref","first-page":"ofx084","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review","volume":"4","author":"Cosimi","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2018.01.001_bib0100","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/jac\/dku114","article-title":"Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective","volume":"69","author":"Alm","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.01.001_bib0105","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijantimicag.2010.02.006","article-title":"In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates","volume":"35","author":"Vidaillac","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.01.001_bib0110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/AAC.01471-15","article-title":"Neutropenia associated with long-term ceftaroline use","volume":"60","author":"LaVie","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.01.001_bib0115","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dkw062","article-title":"High incidence of neutropenia in patients with prolonged ceftaroline exposure","volume":"71","author":"Furtek","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.01.001_bib0120","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1002\/phar.1286","article-title":"Ceftaroline-induced eosinophilic pneumonia","volume":"33","author":"Desai","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2018.01.001_bib0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2146\/ajhp130441","article-title":"Eosinophilic pneumonia induced by ceftaroline","volume":"71","author":"Griffiths","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jgar.2018.01.001_bib0130","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/jac\/dkv478","article-title":"Safety and effectiveness of outpatient parenteral antimicrobial therapy in older people","volume":"71","author":"Mujal","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.01.001_bib0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijid.2014.11.021","article-title":"Supervised self-administration of outpatient parenteral antibiotic therapy: a report from a large tertiary hospital in Australia","volume":"30","author":"Subedi","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2018.01.001_bib0140","doi-asserted-by":"crossref","first-page":"ofu046","DOI":"10.1093\/ofid\/ofu046","article-title":"Ceftaroline in combination with trimethoprim\u2013sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis","volume":"1","author":"Fabre","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2018.01.001_bib0145","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/21548331.2015.1037228","article-title":"Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia","volume":"43","author":"Kaye","year":"1995","journal-title":"Hosp Pract"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518300031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518300031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T16:03:34Z","timestamp":1693411414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716518300031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":29,"alternative-id":["S2213716518300031"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2018.01.001","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DISC: Describing Infections of the Spine treated with Ceftaroline","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2018.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}